Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice

  • Authors:
    • Yuji Naito
    • Kazuhiro Katada
    • Tomohisa Takagi
    • Hisato Tsuboi
    • Yutaka Isozaki
    • Osamu Handa
    • Satoshi Kokura
    • Norimasa Yoshida
    • Hiroshi Ichikawa
    • Toshikazu Yoshikawa
  • View Affiliations

  • Published online on: June 1, 2006     https://doi.org/10.3892/ijmm.17.6.997
  • Pages: 997-1004
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to elucidate the beneficial effects of rosuvastatin, a new HMG-CoA reductase inhibitor, on colonic mucosal damage and on the inflammatory response in a dextran sulfate sodium (DSS) colitis model. Acute colitis was induced using 8% DSS in female BALB/c mice. Colonic mucosal inflammation was evaluated clinically, biochemically, and histologically. Mucosal protein contents and mRNA levels of tumor necrosis factor (TNF)-α were determined by immunoassay and real time-PCR. The mRNA levels of endothelial nitric oxide synthase (eNOS) were determined by real-time PCR. Disease activity scores in DSS-induced colitis model mice, as determined by weight loss, stool consistency, and blood in stool, were significantly lower in the rosuvastatin-treated mice than in control mice. Shortening of the colon was significantly reversed by rosuvastatin. Increases in tissue-associated myeloperoxidase activity and thiobarbituric acid-reactive substances after DSS administration were both significantly inhibited by treatment with rosuvastatin. Rosuvastatin also inhibited increases in intestinal TNF-α protein and mRNA expression after DSS administration, respectively. The mucosal mRNA levels of eNOS were decreased after DSS administration, but preserved in mice treated with rosuvastatin. These results suggest that rosuvastatin prevents the development of DSS-induced colitis in mice via the inhibition of mucosal inflammatory responses associated with the preservation of eNOS transcription.

Related Articles

Journal Cover

June 2006
Volume 17 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Naito Y, Katada K, Takagi T, Tsuboi H, Isozaki Y, Handa O, Kokura S, Yoshida N, Ichikawa H, Yoshikawa T, Yoshikawa T, et al: Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 17: 997-1004, 2006
APA
Naito, Y., Katada, K., Takagi, T., Tsuboi, H., Isozaki, Y., Handa, O. ... Yoshikawa, T. (2006). Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. International Journal of Molecular Medicine, 17, 997-1004. https://doi.org/10.3892/ijmm.17.6.997
MLA
Naito, Y., Katada, K., Takagi, T., Tsuboi, H., Isozaki, Y., Handa, O., Kokura, S., Yoshida, N., Ichikawa, H., Yoshikawa, T."Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice". International Journal of Molecular Medicine 17.6 (2006): 997-1004.
Chicago
Naito, Y., Katada, K., Takagi, T., Tsuboi, H., Isozaki, Y., Handa, O., Kokura, S., Yoshida, N., Ichikawa, H., Yoshikawa, T."Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice". International Journal of Molecular Medicine 17, no. 6 (2006): 997-1004. https://doi.org/10.3892/ijmm.17.6.997